Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow ILMN
Illumina, Inc. (ILMN) EBITDA
Illumina, Inc.'s EBITDA for fiscal 2025 was $1.1B, compared with −$479.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.2B. Over the past ten years it has ranged from −$3.8B (fiscal 2022) to $1.2B (fiscal 2019); the current reading is higher than 82% of that period. EBITDA has risen for 3 consecutive fiscal years. Illumina, Inc. ranks 9th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.1B | — |
| FY2024 | −$479.0M | — |
| FY2023 | −$637.0M | — |
| FY2022 | −$3.8B | — |
| FY2021 | $160.0M | (80.17%) |
| FY2020 | $807.0M | (33.80%) |
| FY2019 | $1.2B | 10.52% |
| FY2018 | $1.1B | 39.27% |
| FY2017 | $792.0M | 4.49% |
| FY2016 | $758.0M | (2.70%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $315.0M | 13.31% |
| Mar 2026 | $278.0M | 3.73% |
| Dec 2025 | $268.0M | (8.84%) |
| Sep 2025 | $294.0M | 4.26% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| IQV IQVIA Holdings Inc. compare | $3.4B |
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| A Agilent Technologies, Inc. compare | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.6B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ILMN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement